Physiomics Awarded New Contract by Numab

AI SummaryClose X

Physiomics plc has secured a new contract with Numab Therapeutics AG to support the pre-clinical development of a multi-specific antibody for autoimmune diseases. This project will involve Physiomics developing a mechanistic Pharmacokinetics and Pharmacodynamics (PK/PD) model to inform quantitative understanding and dosing selection for preclinical and clinical studies, with delivery expected within the financial year ending 2026. This contract further highlights the increasing importance of Model Informed Drug Development approaches in the drug development lifecycle.

Disclaimer*

Companies

Physiomics (PYC)
UK 100

Latest directors dealings